Delivery Order SPE2DX22D0029-SPE2D825F38CA

The U.S. Defense Logistics Agency (DLA), through its Medical Supply Chain division, awarded a delivery order valued at $1,954.56 to AmerisourceBergen Drug Corp on August 2, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract was competitively awarded with no set-aside designation, and performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania.

AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, supplies a comprehensive range of pharmaceutical products and medical supplies to support federal military and veteran healthcare systems through this arrangement. As a critical vendor for the DLA's Pharmaceutical Prime Vendor program, the company delivers brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. This delivery order exemplifies the company's role in fulfilling federal medical supply procurement needs through the broader global pharmaceutical support vehicle.